MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?Zacks Investment Research • Thursday
The world's most sophisticated drug companies are putting billions into vaccines — despite the political environmentMarket Watch • Thursday
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a BuyThe Motley Fool • Monday
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?Zacks Investment Research • 11/06/26
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock RisesZacks Investment Research • 11/06/26
Moderna Hits Five-Year High On Sales Beat; But The Real Story Is Still Its Cancer VaccineInvestors Business Daily • 11/06/26
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher24/7 Wall Street • 11/06/26
Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On FridayBenzinga • 11/06/26
Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.Barrons • 11/06/26